14 Results for "

DSPE-PEG3400-VHPKQHRGGSKGC

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "DSPE-PEG3400-VHPKQHRGGSKGC" in MCE Product Catalog:

Cat. No.: HY-182101B
Target:  

Liposome

Research Areas:  

Others

DSPE-PEG3400-VHPKQHRGGSKGC is a targeted modified phospholipid-polyethylene glycol conjugate covalently coupled to DSPE, PEG, and the vascular-targeting peptide VHPKQHRGGSKGC. DSPE-PEG3400-VHPKQHRGGSKGC can be used for research on tumor vascular imaging and vascular-targeted drug delivery.
loading...
    loading...
Cat. No.: HY-P5112A
Synonyms: Azido-PEG3-FLAG TFA
Research Areas:  

Others

Azido-PEG3-DYKDDDDK (azide-PEG3-FLAG) TFA is a multifunctional fusion tag for the purification of recombinant proteins. Azido-PEG3-DYKDDDDK TFA is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups .
loading...
    loading...
Cat. No.: HY-P5112
CAS No.: 2243206-95-1
Synonyms: Azido-PEG3-FLAG
Research Areas:  

Others

Azido-PEG3-DYKDDDDK (azide-PEG3-FLAG) is a multifunctional fusion tag for the purification of recombinant proteins. Azido-PEG3-DYKDDDDK is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups .
loading...
    loading...
Cat. No.: HY-169089
Target:  

Drug Derivative

Research Areas:  

Cancer

RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .
loading...
    loading...
Cat. No.: HY-P11270
CAS No.: 2843676-09-3
Synonyms: BGM0504; BG128
Research Areas:  

Metabolic Disease

Relsipatide (BG128) is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .
loading...
    loading...
Cat. No.: HY-P11088
CAS No.: 1311293-04-5
VCAM1 binding peptide is a VCAM1 binder with internalization activity. VCAM1 binding peptide can be labeled with 5-FAM. VCAM1 binding peptide serves as a component of biosensing systems for visualizing in vitro VCAM1 endocytic pathways. VCAM1 binding peptide forms the research and development basis for MacroP and NAMP, PET radiotracers targeting VCAM1. VCAM1 binding peptide is applicable to studies related to atherosclerosis .
loading...
    loading...
Cat. No.: HY-169089A
Target:  

Drug Derivative

Research Areas:  

Cancer

RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .
loading...
    loading...
Cat. No.: HY-P10319
Target:  

PKA

Research Areas:  

Cardiovascular Disease Cancer

RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .
loading...
    loading...
Cat. No.: HY-P11088A
VCAM1 binding peptide acetate is a VCAM1 binder with internalization activity. VCAM1 binding peptide acetate can be labeled with 5-FAM. VCAM1 binding peptide acetate serves as a component of biosensing systems for visualizing in vitro VCAM1 endocytic pathways. VCAM1 binding peptide acetate forms the research and development basis for MacroP and NAMP, PET radiotracers targeting VCAM1. VCAM1 binding peptide acetate is applicable to studies related to atherosclerosis .
loading...
    loading...
Cat. No.: HY-P11887
CAS No.: 1174559-81-9
VHPKQHR is a peptide-based delivery enhancer that binds to VCAM-1. VHPKQHR enables intracellular internalization of relevant nanomaterials and facilitates the targeted delivery of miRNA inhibitors to inflamed endothelial cells and endothelial cells activated by disturbed flow. When conjugated with magnetic mesoporous silica nanoparticles, VHPKQHR achieves targeted accumulation at atherosclerotic plaque sites. When displayed on the surface of polyelectrolyte complex micelles, VHPKQHR enhances the relevant effects of anti-miR-92a in Apoe -/- mice. When conjugated with ultrasmall superparamagnetic iron oxide nanoparticles, VHPKQHR forms a contrast agent for T1-weighted magnetic resonance imaging. VHPKQHR can be used in research related to atherosclerosis, stenosis and rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-P11088F
VCAM1 binding peptide, FITC labeled acetate is a FITC-labeled VCAM1 binding peptide acetate (HY-P11088A). VCAM1 binding peptide acetate is a VCAM1 binder with internalization activity. VCAM1 binding peptide acetate serves as a component of biosensing systems for visualizing in vitro VCAM1 endocytic pathways. VCAM1 binding peptide acetate forms the research and development basis for MacroP and NAMP, PET radiotracers targeting VCAM1. VCAM1 binding peptide acetate is applicable to studies related to atherosclerosis .
loading...
    loading...
loading...
    loading...
Cat. No.: HY-P11488
JR11-PEG3-DOTA-PSMA-03 (Compound 2) is an RDC-related compound containing the chelating agent DOTA (HY-W053583), the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-DOTA-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 94.0 nM, 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-DOTA-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
loading...
    loading...
Cat. No.: HY-P11485
JR11-PEG3-HBED-CC-PSMA-03 (Compound 1) is an RDC-related compound containing the chelating agent HBED-CC, the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-HBED-CC-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 59.2 nM, 57.0 nM, respectively. JR11-PEG3-HBED-CC-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-HBED-CC-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
loading...
    loading...
  • 1